CANbridge Pharmaceuticals Inc. (HKG:1228)
Hong Kong
· Delayed Price · Currency is HKD 2.600
+0.110 (4.42%)
At close: Mar 10, 2026
CANbridge Pharmaceuticals Revenue
CANbridge Pharmaceuticals had revenue of 22.25M CNY in the half year ending June 30, 2025, a decrease of -48.32%. This brings the company's revenue in the last twelve months to 62.56M, down -40.20% year-over-year. In the year 2024, CANbridge Pharmaceuticals had annual revenue of 85.10M, down -17.27%.
Revenue (ttm)
62.56M CNY
Revenue Growth
-40.20%
P/S Ratio
18.57
Revenue / Employee
1.39M CNY
Employees
45
Market Cap
1.27B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Beijing Biostar Pharmaceuticals | 58.66M |
| Kintor Pharmaceutical | 12.04M |
| Mabpharm | 464.53M |
| Cutia Therapeutics | 274.31M |
| Wuhan YZY Biopharma | 163.65M |
| Zhaoke Ophthalmology | 38.74M |
| ImmuneOnco Biopharmaceuticals (Shanghai) | 134.60M |
| Transcenta Holding | 10.31M |
CANbridge Pharmaceuticals News
- 7 months ago - China's Push To Expand Access To Costly Therapies And A Partnership Deal Boost Rare Drugs Maker - But Is It Enough? - Benzinga